Navigation Links
GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
Date:12/11/2008

WASHINGTON, Dec. 11 /PRNewswire-FirstCall/ -- The following is GlaxoSmithKline's (NYSE: GSK) statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK's Serevent(R) (salmeterol) and Advair(R) (salmeterol/fluticasone proprionate).

"We welcome the committee's endorsement of Advair as a safe and effective treatment for asthma in adults and children," said Dr. Ellen Strahlman, Chief Medical Officer for GSK. "We believe this recommendation is consistent with national treatment guidelines -- based on evidence and developed by experts -- that support the combination of a LABA and ICS as a preferred treatment for children and adults with persistent asthma. We will continue to work with physicians to encourage broader understanding of national guidelines for appropriate use."

"Serevent, when used with an ICS, is an important treatment option for some patients as outlined in national guidelines. We are confident that our proposed new labeling, medication guide and risk management plan would help physicians safely manage the appropriate use of Serevent in conjunction with an ICS," Dr. Strahlman said. "We are concerned that -- if the FDA adopts the panel's recommendation on Serevent -- it is possible that Serevent would be severely restricted and deny patients needed treatment for optimal care of their asthma."

GSK is committed to continuing discussions with the Agency as it determines next steps following the Advisory Committee meeting.

GSK conducted an analysis of more than 200 clinical studies that included more than 100,000 patients, presenting the following information to the committees:

-- The clinical and observational data presented by GSK demonstrated better overall asthma contr
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
2. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
3. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
4. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
7. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
8. GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business
9. IADR and GlaxoSmithKline Consumer Healthcare announce winners
10. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
11. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Over the past decade, the ... which has affected the Medical Group Practice Management ... regular hours, more young physicians are opting out of ... groups,” says IBISWorld industry analyst Anna Son. In addition, ... number of older physicians are selling their practices and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Vegas ... is pleased to announce all new vacation packages ... in coming to Las Vegas for this patriotic ... it is thanks to VegasHotelEscapes.com's new special pricing ... to state that it guarantees the lowest prices ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
Breaking Medicine News(10 mins):Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... Nov. 1 It is estimated more than two ... States, with about,one-in-six expected to get the disease at ... Society. Thankfully, new treatment,technologies are making surviving the disease ... and more Americans are too large to be treated,using ...
... Nov. 1 The Michael J. Fox,Foundation (MJFF) ... 2008 Target Validation effort. Under this annual program ... 2008 for projects designed to validate the,therapeutic potential ... possible pharmaceutical industry investment and clinical trials., ...
... discovered a novel mechanism to predict survival in older ... have significant implications for new treatment approaches. , For ... aromatase, an enzyme that naturally makes estrogen from another ... survival rates in women over 65 with Stage 1 ...
... do not necessarily have worse outcomes after liver transplantation. ... they fare just as well. These are the results ... Hepatology, a journal published by John Wiley & Sons ... of Liver Diseases (AASLD). The article is also available ...
... carbon nanotubes can be destroyed by non-invasive radio waves ... a research team led by scientists at The University ... University has shown in preclinical experiments. , In a ... journal Cancer, researchers show that the technique completely destroyed ...
... keeping good track of daily blood sugar levels, while ... -- Fewer American adults with diabetes are developing cardiovascular ... blood sugar levels, according to new U.S. government research ... and Prevention studies, published in the CDC,s weekly journal ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:Researchers discover new way to predict survival in older women with lung cancer 2Health News:Researchers discover new way to predict survival in older women with lung cancer 3Health News:No racial differences seen in outcomes after liver transplantation 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 3Health News:Adults With Diabetes Doing Better Prevention Job 2
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... , May 23, 2013  A recently published clinical ... Houston, Texas , demonstrates that 3D mammography ... cancer detection. The study, "Implementation of ... Study," was led by Stephen L. Rose ... of the American Journal of Roentgenology (AJR). ...
(Date:5/23/2013)... JERUSALEM , May 23, 2013  Hadasit Bio-Holdings ... portfolio of biotech companies, based on intellectual property ... Israel ,s foremost medical research center, ... Neurosciences Ltd., received significant funding from the Israeli ... Chief Scientist (OCS) to support product development and ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ... biopharmaceutical,company, announced today that preliminary findings from ... treatment with AVR118,appears to have clinical activity ... incisions or dermatologic,dermabrasion., The Phase II open ...
... -- More than 70 abstracts highlight VELCADE efficacy ... care --, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ ... the market leading therapy with unsurpassed single-agent,efficacy for ... featured at the upcoming International Myeloma,Workshop (IMW) in ...
Cached Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
The new Vascular ClearWay Irrigating PTFE Balloon Catheter is a revolutionary micro-porous PTFE balloon catheter designed for the removal of fresh, soft emboli and thrombi, and for intraluminal irrig...
... for every general surgery need. No matter ... the GO450/GO400 Omni-Flex™ General Retractor Systems give ... the best possible exposure in the simplest ... and the hinged extension arm, the GO450 ...
... gelatinase-associated lipocalin, lipocalin-2) is a new early ... renal failure with a >90% positive predictive ... urine, as early as 2 hours after ... diagnostic marker for acute renal failure. ,Quantitative ...
... Don't miss the sounds you ... lung, and other body sounds ... with the Littmann Model 3000., ... technology, up to 18 times ...
Medicine Products: